Drugs / BCG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04975178 Comparator | Oct 2022 → Feb 2029 expected | tuberculosis | Biofabri, S.L | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04975178 ↗ |
| Modality | Vaccine | “BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis.” NCT04975178 ↗ |